ReviewCureus2025
Bisphosphonate-Related Atypical Femoral Fractures: A Comprehensive Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bisphosphonates have become a cornerstone in the management of osteoporosis and other bone-related conditions over the past few decades. While these medications have proven highly effective in reducing the risk of typical osteoporotic fractures, a concerning paradox has emerged: long-term use may be associated with a rare but serious complication known as atypical femoral fractures (AFFs). These unusual breaks occur in the shaft of the femur and differ significantly from common osteoporotic fractures in terms of location, appearance, and mechanism. This review explores the nature of these fractures by examining their characteristics, underlying mechanisms, risk factors, clinical presentation, diagnostic approaches, and management strategies. Understanding this complication is essential for clinicians who prescribe bisphosphonates and for patients who take them, as it highlights the importance of balancing the substantial benefits of these medications with their potential risks - particularly with prolonged use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.